Clinical trial MCLA-129-CL01
Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Merus |
| EudraCT Identifier | 2021-000203-20 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04868877 |
| Last update |